Polyphor parlays a pathogen-specific antibiotic and I/O work into a $165M IPO for its PhIII program
Polyphor has successfully completed an IPO, raising about $165 million to back its Phase III development of a new antibiotic specifically designed to counterattack against …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.